ProQR Therapeutics N.V.

ProQR Therapeutics N.V., based in Leiden, develops medicines that aim to edit RNA, the temporary messages cells use to make proteins. Its Axiomer platform recruits an enzyme already present in the body to change a selected letter in that message. The intended change is to RNA, not a permanent rewrite of the patient’s DNA.

The company is still developing and testing its therapies. It has no approved product from this platform. Its business combines an internal pipeline with research partnerships, including work with Eli Lilly. Reported revenue comes from collaboration arrangements, not routine sales of an approved medicine.